Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard and Oncotype DX tests, Exact Sciences ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

Craig-Hallum analyst Bill Bonello lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the ...

Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Exact Sciences (EXAS) to $60 from $80 and keeps an Outperform rating ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

Recent data published Oct. 7 indicate that it is not plausible to increase the maximum human lifespan muchbeyond historical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

(2) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common ...